Gamco Investors INC. ET AL Purchases 44,110 Shares of DENTSPLY SIRONA Inc. $XRAY

Gamco Investors INC. ET AL grew its position in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 38.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 158,803 shares of the medical instruments supplier’s stock after buying an additional 44,110 shares during the quarter. Gamco Investors INC. ET AL owned 0.08% of DENTSPLY SIRONA worth $2,015,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Arizona State Retirement System raised its holdings in DENTSPLY SIRONA by 1.4% in the 3rd quarter. Arizona State Retirement System now owns 58,952 shares of the medical instruments supplier’s stock worth $748,000 after acquiring an additional 807 shares during the last quarter. True Wealth Design LLC boosted its stake in DENTSPLY SIRONA by 49.7% during the 3rd quarter. True Wealth Design LLC now owns 3,557 shares of the medical instruments supplier’s stock valued at $45,000 after purchasing an additional 1,181 shares during the last quarter. Sivia Capital Partners LLC increased its holdings in shares of DENTSPLY SIRONA by 5.3% in the 3rd quarter. Sivia Capital Partners LLC now owns 25,774 shares of the medical instruments supplier’s stock worth $327,000 after purchasing an additional 1,293 shares in the last quarter. Empowered Funds LLC raised its stake in shares of DENTSPLY SIRONA by 8.8% in the first quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock worth $244,000 after purchasing an additional 1,320 shares during the last quarter. Finally, Parkside Financial Bank & Trust raised its stake in shares of DENTSPLY SIRONA by 620.6% in the second quarter. Parkside Financial Bank & Trust now owns 1,715 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 1,477 shares during the last quarter. Institutional investors own 95.70% of the company’s stock.

Insider Activity at DENTSPLY SIRONA

In other DENTSPLY SIRONA news, Director James D. Forbes purchased 5,000 shares of the firm’s stock in a transaction on Monday, March 9th. The shares were acquired at an average cost of $12.48 per share, for a total transaction of $62,400.00. Following the completion of the transaction, the director owned 10,000 shares of the company’s stock, valued at approximately $124,800. The trade was a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Gregory T. Lucier purchased 15,000 shares of the company’s stock in a transaction dated Monday, March 9th. The shares were acquired at an average price of $12.45 per share, for a total transaction of $186,750.00. Following the purchase, the director directly owned 65,000 shares in the company, valued at approximately $809,250. The trade was a 30.00% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 70,000 shares of company stock valued at $956,437 over the last 90 days. 0.52% of the stock is currently owned by company insiders.

Key DENTSPLY SIRONA News

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: FDA clearance for a dental‑dedicated MRI (ddMRI) with Siemens Healthineers: this first‑of‑its‑kind imaging system expands XRAY’s advanced‑imaging addressable market and could drive higher‑margin equipment sales and recurring service revenue over time. First-ever Dental Dedicated MRI Validated…
• Positive Sentiment: Insider buying from directors (James Forbes and Gregory Lucier): recent purchases (~$12.45–$12.48/share) signal management/board confidence in the stock at current levels and can support sentiment if the buys continue. DENTSPLY SIRONA (NASDAQ:XRAY) Director James Forbes Buys 5,000 Shares
• Neutral Sentiment: Analysts are reworking valuation and risk assumptions: coverage shifts and updated models (discussed in a Yahoo Finance piece) are causing targets and ratings to be revisited — this fuels near‑term volatility but could clarify consensus levels over weeks. How The Dentsply Sirona (XRAY) Story Is Shifting…
• Neutral Sentiment: Presentation transcript from the Leerink Global Healthcare Conference: useful for incremental detail on strategy, margin actions and product cadence — may influence analyst revisions but no single headline takeaway. DENTSPLY SIRONA Presents at Leerink…
• Neutral Sentiment: Short‑interest reports show data anomalies (reported as 0 shares / 0 days to cover) — current disclosures appear unreliable, so there is no clear short‑squeeze or elevated short‑pressure signal from these entries. (Data point: average volume references included in filings.)
• Negative Sentiment: Recent quarterly results/earnings mix: revenue beat but an EPS miss and a negative net margin keep focus on profitability and leverage (market cap and leverage metrics remain notable). Analysts’ target adjustments are mixed (some cuts, some raises), leaving consensus at a “Hold” with average target ~$14.4 — downside remains if execution or margin recovery slows. DENTSPLY SIRONA (XRAY) MarketBeat summary

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Barclays initiated coverage on DENTSPLY SIRONA in a research report on Monday, December 8th. They set an “underweight” rating and a $12.00 price objective on the stock. Bank of America upgraded shares of DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and upped their target price for the company from $13.00 to $17.00 in a research note on Thursday, February 19th. UBS Group reduced their price target on shares of DENTSPLY SIRONA from $17.00 to $16.00 and set a “buy” rating for the company in a research note on Tuesday, February 3rd. Mizuho boosted their price objective on shares of DENTSPLY SIRONA from $14.00 to $16.00 and gave the company a “neutral” rating in a report on Monday, March 2nd. Finally, Zacks Research upgraded shares of DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a research report on Monday, March 2nd. Three investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $14.42.

DENTSPLY SIRONA Stock Down 0.9%

XRAY stock opened at $12.68 on Wednesday. The company has a market cap of $2.53 billion, a price-to-earnings ratio of -4.23, a P/E/G ratio of 1.50 and a beta of 0.97. The company has a debt-to-equity ratio of 1.50, a quick ratio of 1.03 and a current ratio of 1.51. The business’s 50-day moving average is $12.69 and its two-hundred day moving average is $12.43. DENTSPLY SIRONA Inc. has a fifty-two week low of $9.85 and a fifty-two week high of $17.18.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. The firm had revenue of $961.00 million for the quarter, compared to the consensus estimate of $926.40 million. During the same quarter in the prior year, the firm earned $0.26 earnings per share. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, analysts forecast that DENTSPLY SIRONA Inc. will post 1.84 earnings per share for the current year.

DENTSPLY SIRONA Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.